Trial
NCT03682055
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Cullinan Therapeutics Inc.
Collaborators
National Cancer Institute (NCI)
Condition
Nasopharyngeal Carcinoma
Intervention
VK-2019
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-15